Új, hazai lehetoség a tartós orális antikoaguláns terápiában

Translated title of the contribution: A new way of long-term oral anticoagulant therapy in Hungary

Research output: Contribution to journalArticle

Abstract

Coumarins have been widely used for the prevention of arterial and venous thromboembolism. The importance of oral anticoagulants has steadily increased in internal medicine and cardiology in the past 20 years. Coumarins are vitamin K antagonists by inhibiting the synthesis of vitamin K-dependent coagulation factors in liver cells. Since the average half-life of hydroxy-coumarin is longer than that of aceno-coumarin, the INR of patients treated with hydroxy-coumarin is more stable, thus making it especially suitable for long-term anticoagulant treatment. The main indications of coumarin therapy include secondary prophylaxis of venous thromboembolism, and primary and secondary prevention of arterial thromboembolism, particularly embolic stoke, in patients with cardiovascular disorders. This review summarizes the most important clinical issues of long-term oral anticoagulant therapy including indications, contraindications, dosing, therapeutic range, and laboratory monitoring. Special emphasis is placed on the role of hydroxy-coumarin in long-term oral anticoagulant therapy.

Original languageHungarian
Pages (from-to)203-210
Number of pages8
JournalLege Artis Medicinae
Volume16
Issue number3
Publication statusPublished - Mar 2006

Fingerprint

Hungary
Anticoagulants
Coumarins
Vitamin K
Venous Thromboembolism
Therapeutics
Blood Coagulation Factors
International Normalized Ratio
Thromboembolism
Primary Prevention
Internal Medicine
Secondary Prevention
Cardiology
Half-Life
coumarin
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Új, hazai lehetoség a tartós orális antikoaguláns terápiában. / Boda, Z.

In: Lege Artis Medicinae, Vol. 16, No. 3, 03.2006, p. 203-210.

Research output: Contribution to journalArticle

@article{be4c2b79cd5d403e8326fce349e0a9b5,
title = "{\'U}j, hazai lehetos{\'e}g a tart{\'o}s or{\'a}lis antikoagul{\'a}ns ter{\'a}pi{\'a}ban",
abstract = "Coumarins have been widely used for the prevention of arterial and venous thromboembolism. The importance of oral anticoagulants has steadily increased in internal medicine and cardiology in the past 20 years. Coumarins are vitamin K antagonists by inhibiting the synthesis of vitamin K-dependent coagulation factors in liver cells. Since the average half-life of hydroxy-coumarin is longer than that of aceno-coumarin, the INR of patients treated with hydroxy-coumarin is more stable, thus making it especially suitable for long-term anticoagulant treatment. The main indications of coumarin therapy include secondary prophylaxis of venous thromboembolism, and primary and secondary prevention of arterial thromboembolism, particularly embolic stoke, in patients with cardiovascular disorders. This review summarizes the most important clinical issues of long-term oral anticoagulant therapy including indications, contraindications, dosing, therapeutic range, and laboratory monitoring. Special emphasis is placed on the role of hydroxy-coumarin in long-term oral anticoagulant therapy.",
keywords = "Contraindications, Coumarins, Hydroxy-coumarin, Indications, Laboratory monitoring, Long-term oral anticoagulant therapy, Side effects",
author = "Z. Boda",
year = "2006",
month = "3",
language = "Hungarian",
volume = "16",
pages = "203--210",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3",

}

TY - JOUR

T1 - Új, hazai lehetoség a tartós orális antikoaguláns terápiában

AU - Boda, Z.

PY - 2006/3

Y1 - 2006/3

N2 - Coumarins have been widely used for the prevention of arterial and venous thromboembolism. The importance of oral anticoagulants has steadily increased in internal medicine and cardiology in the past 20 years. Coumarins are vitamin K antagonists by inhibiting the synthesis of vitamin K-dependent coagulation factors in liver cells. Since the average half-life of hydroxy-coumarin is longer than that of aceno-coumarin, the INR of patients treated with hydroxy-coumarin is more stable, thus making it especially suitable for long-term anticoagulant treatment. The main indications of coumarin therapy include secondary prophylaxis of venous thromboembolism, and primary and secondary prevention of arterial thromboembolism, particularly embolic stoke, in patients with cardiovascular disorders. This review summarizes the most important clinical issues of long-term oral anticoagulant therapy including indications, contraindications, dosing, therapeutic range, and laboratory monitoring. Special emphasis is placed on the role of hydroxy-coumarin in long-term oral anticoagulant therapy.

AB - Coumarins have been widely used for the prevention of arterial and venous thromboembolism. The importance of oral anticoagulants has steadily increased in internal medicine and cardiology in the past 20 years. Coumarins are vitamin K antagonists by inhibiting the synthesis of vitamin K-dependent coagulation factors in liver cells. Since the average half-life of hydroxy-coumarin is longer than that of aceno-coumarin, the INR of patients treated with hydroxy-coumarin is more stable, thus making it especially suitable for long-term anticoagulant treatment. The main indications of coumarin therapy include secondary prophylaxis of venous thromboembolism, and primary and secondary prevention of arterial thromboembolism, particularly embolic stoke, in patients with cardiovascular disorders. This review summarizes the most important clinical issues of long-term oral anticoagulant therapy including indications, contraindications, dosing, therapeutic range, and laboratory monitoring. Special emphasis is placed on the role of hydroxy-coumarin in long-term oral anticoagulant therapy.

KW - Contraindications

KW - Coumarins

KW - Hydroxy-coumarin

KW - Indications

KW - Laboratory monitoring

KW - Long-term oral anticoagulant therapy

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=33645457595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645457595&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 203

EP - 210

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3

ER -